Aliases & Classifications for Phobic Disorder

MalaCards integrated aliases for Phobic Disorder:

Name: Phobic Disorder 12 15 17
Phobic Anxiety Disorder 70
Phobic Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:591
ICD9CM 34 300.20
MeSH 44 D010698
NCIt 50 C35420
SNOMED-CT 67 52039009
ICD10 32 F40 F40.9
UMLS 70 C0349231

Summaries for Phobic Disorder

Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to agoraphobia and phobia, specific. An important gene associated with Phobic Disorder is PRODH (Proline Dehydrogenase 1), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and cAMP signaling pathway. The drugs Paroxetine and Clonazepam have been mentioned in the context of this disorder. Affiliated tissues include eye, amygdala and breast, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 A phobia is a type of anxiety disorder defined by a persistent and excessive fear of an object or... more...

Related Diseases for Phobic Disorder

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 agoraphobia 31.4 SLC6A4 MAOA HTR2A HTR1A CTU2 CRHR1
2 phobia, specific 30.7 SLC6A4 PRODH OXT MAOA HTR2A HTR1A
3 social phobia 30.4 SLC6A4 SERPINA3 PRODH OXT MIR485 MAOA
4 bulimia nervosa 30.1 SLC6A4 OXT MAOA HTR2A COMT BDNF
5 avoidant personality disorder 30.1 MAOA AMY1C AMY1B AMY1A
6 tic disorder 29.9 SLC6A4 SLC6A3 PRODH MAOA HTR2A COMT
7 depression 29.8 SLC6A4 MAOA HTR2A HTR1A CRHR1 CRH
8 adjustment disorder 29.7 SLC6A4 POMC OXT HTR2A HTR1A CRH
9 generalized anxiety disorder 29.7 SLC6A4 SLC6A3 MAOA HTR2A HTR1A CRHR1
10 neurotic disorder 29.6 SLC6A4 POMC OXT MAOA HTR2A HTR1A
11 acute stress disorder 29.6 SLC6A4 SERPINA3 POMC OXT HTR1A CRHR1
12 alcohol use disorder 29.6 SLC6A4 SLC6A3 PRODH HTR2A HTR1A CRHR1
13 anorexia nervosa 29.4 SLC6A4 POMC OXT MAOA HTR2A HTR1A
14 eating disorder 29.4 SLC6A4 SLC6A3 POMC OXTR HTR2A CRH
15 personality disorder 29.4 SLC6A4 SLC6A3 OXTR MAOA HTR2A HTR1A
16 alcohol dependence 29.3 SLC6A4 SLC6A3 POMC MAOA HTR2A HTR1A
17 substance dependence 29.3 SLC6A4 SLC6A3 SERPINA3 POMC MAOA CRHR1
18 psychotic disorder 29.3 SLC6A4 SLC6A3 SERPINA3 PRODH OXT MAOA
19 post-traumatic stress disorder 29.3 SLC6A4 POMC OXTR MAOA HTR2A CRHR1
20 dysthymic disorder 29.0 SLC6A4 SLC6A3 PRODH POMC MAOA HTR2A
21 obsessive-compulsive disorder 29.0 SLC6A4 SLC6A3 POMC OXTR OXT MAOA
22 substance abuse 28.9 SLC6A4 SLC6A3 SERPINA3 PRODH POMC MAOA
23 panic disorder 28.9 SLC6A4 SLC6A3 POMC MAOA HTR2A HTR1A
24 mental depression 28.5 SLC6A4 SLC6A3 SERPINA3 PRODH POMC OXTR
25 major depressive disorder 28.2 SLC6A4 SLC6A3 POMC OXTR OXT MAOA
26 anxiety 28.0 SLC6A4 SLC6A3 PRODH POMC OXTR OXT
27 animal phobia 10.4 SLC6A4 OXT
28 narcissistic personality disorder 10.4 OXT MAOA
29 corneal dystrophy, lisch epithelial 10.4 MAOA HTR1A
30 pedophilia 10.4 OXT MAOA
31 voyeurism 10.4 SERPINA3 PRODH MAOA
32 aspiration pneumonitis 10.4 SERPINA3 OXT
33 schizoid personality disorder 10.4 PRODH FMR1
34 paraphilia disorder 10.4 SLC6A4 OXT MAOA
35 flying phobia 10.4 OXT MAOA COMT
36 barbiturate abuse 10.3 POMC MAOA
37 dissociative disorder 10.3 SLC6A4 OXT BDNF
38 brunner syndrome 10.3 SLC6A4 MAOA COMT
39 oculogyric crisis 10.3 PRODH HTR2A HTR1A
40 tardive dyskinesia 10.3 HTR2A COMT
41 hypoactive sexual desire disorder 10.3 OXT HTR2A HTR1A
42 ectopic cushing syndrome 10.3 POMC CRH
43 cyclothymic disorder 10.3 SLC6A4 HTR2A COMT
44 amnestic disorder 10.3 OXT HTR1A BDNF
45 obsessive-compulsive personality disorder 10.3 SLC6A4 HTR2A COMT
46 schizotypal personality disorder 10.3 PRODH HTR2A COMT
47 placenta disease 10.3 SERPINA3 PRODH OXT
48 myofascial pain syndrome 10.3 POMC BDNF
49 childhood disintegrative disease 10.3 OXT FMR1 BDNF
50 pituitary infarct 10.3 POMC CRH

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder

Symptoms & Phenotypes for Phobic Disorder

GenomeRNAi Phenotypes related to Phobic Disorder according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-101 9.97 POMC
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.97 AMY1A AMY1B AMY1C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 9.97 SLC6A4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 9.97 POMC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.97 AMY1A AMY1B AMY1C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-136 9.97 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.97 PRODH SLC6A4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.97 POMC
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.97 AMY1A AMY1B AMY1C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-192 9.97 PRODH
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 9.97 PRODH SLC6A4
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.97 PRODH
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.97 POMC
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 9.97 PRODH
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.97 SLC6A4
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-5 9.97 PRODH
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.97 PRODH
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.97 POMC
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.97 AMY1A AMY1B AMY1C PRODH
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-9 9.97 POMC
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-90 9.97 SLC6A4

MGI Mouse Phenotypes related to Phobic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 BDNF COMT CRH CRHR1 FMR1 HTR1A
2 endocrine/exocrine gland MP:0005379 9.9 BDNF COMT CRH CRHR1 FMR1 HTR2A
3 integument MP:0010771 9.65 BDNF CRH FMR1 OXT OXTR POMC
4 nervous system MP:0003631 9.44 BDNF COMT CRH CRHR1 FMR1 HTR1A

Drugs & Therapeutics for Phobic Disorder

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
2
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Sertraline Approved Phase 4 79617-96-2 68617
5
Topiramate Approved Phase 4 97240-79-4 5284627
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
8 Cytochrome P-450 Enzyme Inhibitors Phase 4
9 Quetiapine Fumarate Phase 4 111974-72-2
10 Antipsychotic Agents Phase 4
11 Venlafaxine Hydrochloride Phase 4
12 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
13 GABA Modulators Phase 4
14 Neurotransmitter Agents Phase 4
15 Antidepressive Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Serotonin Uptake Inhibitors Phase 4
18 Anticonvulsants Phase 4
19 Hypoglycemic Agents Phase 4
20 Analgesics Phase 4
21 Poke Phase 4
22
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
23
Cycloserine Approved Phase 3 68-41-7 401 6234
24
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
25
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
26
Yohimbine Approved, Investigational, Vet_approved Phase 2, Phase 3 146-48-5 8969
27
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
28
Dexetimide Withdrawn Phase 2, Phase 3 21888-98-2
29 Anti-Infective Agents Phase 3
30 Antibiotics, Antitubercular Phase 3
31 Antimetabolites Phase 3
32 Anti-Bacterial Agents Phase 3
33 Antitubercular Agents Phase 3
34 Yohimbe Phase 2, Phase 3
35
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
36
Guanfacine Approved, Investigational Phase 2 29110-47-2 3519
37
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
38
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
39
St. John's Wort Approved, Investigational, Nutraceutical Phase 2 84082-80-4
40 Antiviral Agents Phase 2
41 Adrenergic alpha-Agonists Phase 2
42 Adrenergic Agents Phase 2
43 Adrenergic Agonists Phase 2
44 Antihypertensive Agents Phase 2
45 Nootropic Agents Phase 1, Phase 2
46 Anti-Anxiety Agents Phase 2
47 Narcotics Phase 2
48 Analgesics, Opioid Phase 2
49 Narcotic Antagonists Phase 2
50 glucocorticoids Phase 2

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
2 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
3 Improving Outcomes in Pharmacotherapy of Social Phobia Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
4 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
5 Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial. Terminated NCT00182455 Phase 4 Topiramate;Placebo
6 A Randomized Controlled Study of the Effect of a Needle Phobia or Apprehension Intervention With or Without Synera® on Conversion From Central Venous Catheters to Arteriovenous Fistula or Graft Terminated NCT01623583 Phase 4
7 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice (SophoPrax) Unknown status NCT01388231 Phase 2, Phase 3
8 Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3 Escitalopram
9 Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes Completed NCT01102803 Phase 3 D-Cycloserine;Placebo
10 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
11 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
12 Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial Completed NCT00326430 Phase 2, Phase 3
13 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
14 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
15 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study> Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
16 A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT) Completed NCT00564967 Phase 3
17 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
18 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
19 The Efficacy of a VR Enhanced Video Exposure Therapy for Dental Phobia - a Randomized Controlled Trial Unknown status NCT03098134 Phase 2
20 Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety Completed NCT02816684 Phase 2
21 Effect of D-Cycloserine on Treatment of Social Phobia Completed NCT00128401 Phase 2 D-Cycloserine;Placebo
22 One-Session Treatment for Specific Phobias in Children Completed NCT00051220 Phase 1, Phase 2
23 St. John's Wort Versus Placebo in Social Phobia Completed NCT00035412 Phase 2 St. John's Wort
24 A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder. Completed NCT02432703 Phase 2 JNJ-42165279;Placebo
25 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP). Completed NCT01470469 Phase 2 SPD503 (extended-release Guanfacine hydrochloride);Placebo
26 Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia Completed NCT01217788 Phase 2 PH94B intranasal spray
27 An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia. Completed NCT00591825 Phase 2 D-cycloserine;Placebo
28 Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training in the Modification of Pathological Fear Completed NCT02926352 Phase 1, Phase 2
29 Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia Completed NCT00872716 Phase 2 Quetiapine XR
30 A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response Completed NCT02218736 Phase 2 CERC-501;placebo
31 Development of Intelligent Virtual Reality Therapy System (IVRTS) and Testing Its Clinical Efficacy: Revolutionizing Evidence-Based Psychotherapy Completed NCT04620447 Phase 1, Phase 2
32 Enhancing Exposure Therapy for Snake and Spider Phobias With Fear Retrieval and Compound Extinction Completed NCT02160470 Phase 1, Phase 2
33 A Brief Behavioral Treatment for Anxiety in Young Children Completed NCT02051192 Phase 1, Phase 2
34 Glucocorticoid Treatment for Social Phobia Terminated NCT01574014 Phase 2 Hydrocortisone;Placebo
35 Time Intensive Cognitive Behavioural Therapy for a Specific Phobia of Vomiting Using a Single Case Experimental Design Completed NCT02920814 Phase 1
36 Neurophysiological Correlates of Exposition Therapy in Spider Phobia Unknown status NCT03653923
37 Virtual Reality and Concept of Control in the Treatment of Acrophobia by Exposure to Virtual Environments: Comparative Test Unknown status NCT02020824
38 Digital IAPT: The Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in the Improving Access to Psychological Therapies Programme Unknown status NCT03188575
39 Internet-delivered Transdiagnostic Intervention for Anxiety and Depression in Romania- A Randomized Control Trial Unknown status NCT02739607
40 Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting Unknown status NCT01075672
41 RECOVERY: An Internet-delivered Transdiagnostic Cognitive Behavior Therapy in Romania Unknown status NCT03917550
42 The Experimental Study of Threat-Avoidance in Anxiety Patients: Behavioral, Emotional, and Neural Correlates Unknown status NCT02336802
43 D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults Unknown status NCT01037101 D-Cycloserine;Placebo
44 Qualitative Evaluation of Therapeutic Alliance in Adolescent Psychiatry: Crossing Perspectives of Adolescents, Parents and Physicians Unknown status NCT03288649
45 Evaluation of Nonsurgical Periodontal Treatment in Patients With Social Phobia: a Randomized Controlled Clinical Trial Unknown status NCT03241277
46 Improving the Control of Fear: Healthy Adults to Pathological Anxiety Unknown status NCT03498599
47 Clinical Evaluation of a Fiber-optic Sensor System for Monitoring Respiration Activity and Heart Work During MRI Examinations Unknown status NCT03384849
48 Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder: A Pilot Study Unknown status NCT01736631
49 Anti-phobic and Safety Behaviors in the Treatment of Acrophobia Unknown status NCT02085343
50 Prediction of Claustrophobia During MR Imaging: An Observational 18-Months Single Center Study Completed NCT01367067

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 70 / NDF-RT 51 :


gabapentin
gabapentin enacarbil
Paroxetine
Paroxetine Hydrochloride

Cochrane evidence based reviews: phobic disorders

Genetic Tests for Phobic Disorder

Anatomical Context for Phobic Disorder

MalaCards organs/tissues related to Phobic Disorder:

40
Eye, Amygdala, Breast, Thyroid, Skin, Ovary, Monocytes

Publications for Phobic Disorder

Articles related to Phobic Disorder:

(show top 50) (show all 413)
# Title Authors PMID Year
1
Virtual Reality Therapy in Mental Health. 61
33606946 2021
2
Life satisfaction in persons with mental disorders. 61
32556822 2020
3
[Diagnose depressive disorder, generalized anxiety disorder, panic disorder, phobic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, adjustment disorder (child to elderly), personality]. 61
33739776 2020
4
Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. 61
32496566 2020
5
Disgust and fear: common emotions between eating and phobic disorders. 61
29766462 2020
6
'Excess anxiety' and 'less anxiety': both depend on vestibular function. 61
31743237 2020
7
[Features of neurological manifestations of the COVID-19 in children and adults]. 61
33081456 2020
8
Prevalence of Common Mental Disorders in South Asia: A Systematic Review and Meta-Regression Analysis. 61
32982812 2020
9
Cortical oxygenation during exposure therapy - in situ fNIRS measurements in arachnophobia. 61
32135488 2020
10
Skin fairness is a better predictor for impaired physical and mental health than hair redness. 61
31792316 2019
11
Anxiety Symptom Severity and Long-term Risk for Suicidal Behavior in Depressive Disorders. 61
31131922 2019
12
[Epidemiology of anxiéty disorders]. 61
32237614 2019
13
[Prognosis of anxiety disorders]. 61
32237615 2019
14
Anxiety symptoms in obsessive-compulsive disorder and generalized anxiety disorder. 61
31760413 2019
15
The Spectrum of Vestibular Migraine: Clinical Features, Triggers, and Examination Findings. 61
30737783 2019
16
The genetic and environmental structure of fear and anxiety in juvenile twins. 61
30708402 2019
17
Risk of psychiatric disorders in rosacea: A nationwide, population-based, cohort study in Taiwan. 61
30466187 2019
18
Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. 61
30760241 2019
19
The Diagnosis and Treatment of Anxiety Disorders. 61
30282583 2018
20
Fine motor ability and psychiatric disorders in youth. 61
29209833 2018
21
Anxiety After Stroke: The Importance of Subtyping. 61
29437982 2018
22
[Cognitive processes in patients with different structure of anxiety disorders]. 61
29652298 2018
23
[Subjective evaluation of the effect of single test doses of phenazepam and placebo in patients with anxiety disorders: a relationship with objective pharmaco-electroencephalography characteristics]. 61
30335073 2018
24
[Frequency of physical symptoms in anxiety-depressive disorders: cross-sectional study in a population of 202 psychiatric consultants]. 61
31037209 2018
25
Common and distinct brain networks underlying panic and social anxiety disorders. 61
28642079 2018
26
Hypnotic approach during dental treatment: analysis of descriptive data of a case series. 61
29460520 2018
27
Do Symptoms of Irritable Bowel Syndrome Improve when Patients Receive Cognitive Behavioural Therapy for Co-morbid Anxiety Disorders in a Primary Care Psychological Therapy (IAPT) Service? 61
28478779 2017
28
Factors related to the association of social anxiety disorder and alcohol use among adolescents: a systematic review. 61
28579354 2017
29
Cultural aspects of anxiety disorders in India. 61
28867936 2017
30
Changes in intensity of neurotic symptoms associated with reduction of suicidal ideation in patients who underwent psychotherapy in the day hospital for the treatment of neurotic and behavioral disorders. 61
28866722 2017
31
Comparing Trauma Exposure, Mental Health Needs, and Service Utilization Across Clinical Samples of Refugee, Immigrant, and U.S.-Origin Children. 61
28585740 2017
32
Fear of Vaginal Penetration in the Absence of Pain as a Separate Category of Female Sexual Dysfunction: A Conceptual Overview. 61
28467769 2017
33
Psychophysiological reactivity of currently dental phobic-, remitted dental phobic- and never-dental phobic individuals during exposure to dental-related and other affect-inducing materials. 61
28012301 2017
34
Mental Disorders in People Affected by Thalidomide. 61
28377012 2017
35
[Psychopathology of anxiety-phobic disorders that led to hospitalization in a psychiatric hospital]. 61
29265082 2017
36
Prevention of Mental Health Disorders Using Internet- and Mobile-Based Interventions: A Narrative Review and Recommendations for Future Research. 61
28848454 2017
37
Choking Phobia : An Uncommon Phobic Disorder, Treated with Behavior Therapy : A Case Report and Review of the Literature. 61
28638212 2016
38
Gambling Problems Among Community Cocaine Users. 61
26983825 2016
39
[Hypnosis for anxiety and phobic disorders: A review of clinical studies]. 61
26944812 2016
40
Disgust- and anxiety-based emotional reasoning in non-clinical fear of vomiting. 61
26117360 2016
41
The High Prevalence of Anxiety Disorders After Stroke. 61
26601725 2016
42
The epidemiology of common mental disorders from age 20 to 50: results from the prospective Zurich cohort Study. 61
25802979 2016
43
Family Aggregation and Risk Factors in Phobic Disorders over Three-Generations in a Nation-Wide Study. 61
26785257 2016
44
[Anxiety and fear in children and adolescents]. 61
27042718 2016
45
[Anxiety disorders diagnostic algorithm in cancer patients]. 61
30462459 2016
46
Psychiatric Morbidity in Patients with Chikungunya Fever: First Report from India. 61
26557595 2015
47
A Critical Comprehensive Review of Religiosity and Anxiety Disorders in Adults. 61
25480317 2015
48
[Anxiety disorders in older adults]. 61
26103112 2015
49
Changes Needed in the Classification of Anxiety Disorders in Childhood: Options for ICD-11. 61
26259415 2015
50
[The strategic psychotherapy in the treatment of mental and behavioral disorders of the anxiety spectrum]. 61
25953942 2015

Variations for Phobic Disorder

Copy number variations for Phobic Disorder from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder

Expression for Phobic Disorder

Search GEO for disease gene expression data for Phobic Disorder.

Pathways for Phobic Disorder

Pathways related to Phobic Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 OXTR OXT CRHR1 CRH
2 12.14 POMC OXTR OXT HTR1A BDNF
3 11.98 SLC6A4 MAOA HTR2A HTR1A BDNF
4 11.79 SLC6A4 MAOA HTR2A HTR1A
5 11.64 POMC CRHR1 CRH
6 11.33 AMY1C AMY1B AMY1A
7
Show member pathways
11.27 SLC6A4 SLC6A3 MAOA
8 10.9 SLC6A4 MAOA HTR2A HTR1A
9
Show member pathways
10.7 MAOA COMT
10
Show member pathways
10.67 SLC6A4 SLC6A3 MAOA COMT
11 10.66 MAOA COMT
12 10.45 AMY1C AMY1B AMY1A
13
Show member pathways
10.38 SLC6A4 SLC6A3 MAOA HTR1A COMT
14 10.28 POMC CRHR1 CRH

GO Terms for Phobic Disorder

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.72 HTR2A HTR1A FMR1 COMT BDNF
2 axon GO:0030424 9.65 SLC6A3 HTR2A FMR1 COMT BDNF
3 integral component of presynaptic membrane GO:0099056 9.33 SLC6A4 SLC6A3 HTR2A
4 extracellular space GO:0005615 9.28 SERPINA3 POMC OXT MIR485 CRH BDNF
5 integral component of postsynaptic membrane GO:0099055 9.13 SLC6A4 SLC6A3 HTR2A

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 POMC OXTR OXT HTR2A HTR1A CRHR1
2 G protein-coupled receptor signaling pathway GO:0007186 10.14 POMC OXTR OXT HTR2A HTR1A CRHR1
3 response to drug GO:0042493 9.85 SLC6A4 SLC6A3 OXTR HTR2A CRH COMT
4 response to estradiol GO:0032355 9.83 SLC6A4 OXTR OXT
5 response to organic cyclic compound GO:0014070 9.81 SLC6A3 OXTR OXT COMT
6 positive regulation of synapse assembly GO:0051965 9.75 OXTR OXT BDNF
7 social behavior GO:0035176 9.73 SLC6A4 OXTR OXT
8 behavior GO:0007610 9.65 HTR2A HTR1A
9 neurotransmitter biosynthetic process GO:0042136 9.64 SLC6A4 SLC6A3
10 catecholamine metabolic process GO:0006584 9.64 MAOA COMT
11 maternal behavior GO:0042711 9.63 OXTR OXT
12 neurotransmitter catabolic process GO:0042135 9.63 MAOA COMT
13 negative regulation of voltage-gated calcium channel activity GO:1901386 9.62 FMR1 CRHR1
14 regulation of dopamine metabolic process GO:0042053 9.62 SLC6A3 HTR1A
15 monoamine transport GO:0015844 9.61 SLC6A4 SLC6A3
16 parturition GO:0007567 9.61 CRHR1 CRH
17 oligosaccharide metabolic process GO:0009311 9.61 AMY1C AMY1B AMY1A
18 positive regulation of uterine smooth muscle contraction GO:0070474 9.59 OXTR OXT
19 serotonin receptor signaling pathway GO:0007210 9.58 HTR2A HTR1A
20 sleep GO:0030431 9.58 OXTR OXT HTR2A
21 negative regulation of gastric acid secretion GO:0060455 9.57 OXTR OXT
22 response to cocaine GO:0042220 9.56 SLC6A3 OXTR OXT CRH
23 positive regulation of penile erection GO:0060406 9.55 OXTR OXT
24 female pregnancy GO:0007565 9.55 OXTR OXT CRHR1 CRH COMT
25 response to ether GO:0045472 9.54 OXT CRH
26 positive regulation of norepinephrine secretion GO:0010701 9.52 OXTR OXT
27 dopamine catabolic process GO:0042420 9.5 SLC6A3 MAOA COMT
28 regulation of corticosterone secretion GO:2000852 9.49 POMC CRHR1
29 regulation of digestive system process GO:0044058 9.48 OXTR OXT
30 regulation of serotonin secretion GO:0014062 9.46 HTR1A CRH
31 sperm ejaculation GO:0042713 9.13 SLC6A4 OXTR OXT
32 memory GO:0007613 9.02 SLC6A4 OXTR OXT HTR2A BDNF

Molecular functions related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cation binding GO:0043169 9.5 AMY1C AMY1B AMY1A
2 chloride ion binding GO:0031404 9.43 AMY1C AMY1B AMY1A
3 monoamine transmembrane transporter activity GO:0008504 9.37 SLC6A4 SLC6A3
4 serotonin binding GO:0051378 9.33 SLC6A4 HTR2A HTR1A
5 alpha-amylase activity (releasing maltohexaose) GO:0103025 9.13 AMY1C AMY1B AMY1A
6 alpha-amylase activity GO:0004556 8.8 AMY1C AMY1B AMY1A

Sources for Phobic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....